JP2023500385A5 - - Google Patents
Info
- Publication number
- JP2023500385A5 JP2023500385A5 JP2022526767A JP2022526767A JP2023500385A5 JP 2023500385 A5 JP2023500385 A5 JP 2023500385A5 JP 2022526767 A JP2022526767 A JP 2022526767A JP 2022526767 A JP2022526767 A JP 2022526767A JP 2023500385 A5 JP2023500385 A5 JP 2023500385A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019117155 | 2019-11-11 | ||
| CNPCT/CN2019/117155 | 2019-11-11 | ||
| PCT/CN2020/128083 WO2021093764A1 (en) | 2019-11-11 | 2020-11-11 | Pharmaceutical combination and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023500385A JP2023500385A (ja) | 2023-01-05 |
| JP2023500385A5 true JP2023500385A5 (OSRAM) | 2023-11-20 |
Family
ID=75911807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526767A Pending JP2023500385A (ja) | 2019-11-11 | 2020-11-11 | 医薬組合せ物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220387417A1 (OSRAM) |
| EP (1) | EP4031179A4 (OSRAM) |
| JP (1) | JP2023500385A (OSRAM) |
| KR (1) | KR20220103961A (OSRAM) |
| CN (1) | CN114901309A (OSRAM) |
| AU (1) | AU2020383580A1 (OSRAM) |
| BR (1) | BR112022009042A2 (OSRAM) |
| CA (1) | CA3160526A1 (OSRAM) |
| IL (1) | IL292646A (OSRAM) |
| MX (1) | MX2022005034A (OSRAM) |
| WO (1) | WO2021093764A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7101169B2 (ja) * | 2016-09-21 | 2022-07-14 | シーストーン ファーマシューティカルズ | プログラム死１（ｐｄ－１）に対する新規モノクローナル抗体 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102675282B (zh) * | 2011-03-15 | 2014-12-24 | 广东东阳光药业有限公司 | 取代的喹啉化合物及其使用方法和用途 |
| US9931401B2 (en) * | 2013-10-08 | 2018-04-03 | Daiichi Sankyo Company, Limited | Combination comprising anti-fibroblast growth factor receptor 2 (FGFR2) antibody and a tyrosine kinase inhibitor |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| WO2016140717A1 (en) * | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| WO2017020291A1 (en) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CN106432501B (zh) * | 2015-08-06 | 2021-07-30 | 基石药业 | 新型抗pd-l1抗体 |
| EP3400014A1 (en) * | 2016-01-08 | 2018-11-14 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
| CN114456269A (zh) * | 2016-09-21 | 2022-05-10 | 基石药业（苏州）有限公司 | 一种新的pd-1单克隆抗体 |
| JP7101169B2 (ja) * | 2016-09-21 | 2022-07-14 | シーストーン ファーマシューティカルズ | プログラム死１（ｐｄ－１）に対する新規モノクローナル抗体 |
| KR20210125094A (ko) * | 2017-04-06 | 2021-10-15 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 비스-링키지를 사용한 세포독성 약물의 접합 |
| CN110536694A (zh) * | 2017-04-20 | 2019-12-03 | Atyr 医药公司 | 用于治疗肺部炎症的组合物和方法 |
| CN109988112A (zh) * | 2017-12-29 | 2019-07-09 | 四川科伦药物研究院有限公司 | 仑伐替尼甲磺酸盐的晶型及其制备方法 |
| CN108379591B (zh) * | 2018-04-03 | 2022-03-29 | 深圳大学 | 免疫激动剂靶向化合物的合成及其应用 |
| CN109731019B (zh) * | 2019-03-07 | 2021-07-16 | 康赋葆(深圳)生物医药科技有限公司 | 一种具有化疗增效作用的组合物，包括组成、制备及应用 |
| CN109867626A (zh) * | 2019-04-18 | 2019-06-11 | 安礼特（上海）医药科技有限公司 | 一种甲磺酸仑伐替尼多晶型物及其制备方法 |
-
2020
- 2020-11-11 JP JP2022526767A patent/JP2023500385A/ja active Pending
- 2020-11-11 EP EP20888069.0A patent/EP4031179A4/en not_active Withdrawn
- 2020-11-11 MX MX2022005034A patent/MX2022005034A/es unknown
- 2020-11-11 WO PCT/CN2020/128083 patent/WO2021093764A1/en not_active Ceased
- 2020-11-11 US US17/776,179 patent/US20220387417A1/en active Pending
- 2020-11-11 CN CN202080078664.3A patent/CN114901309A/zh active Pending
- 2020-11-11 AU AU2020383580A patent/AU2020383580A1/en active Pending
- 2020-11-11 KR KR1020227017523A patent/KR20220103961A/ko not_active Ceased
- 2020-11-11 BR BR112022009042A patent/BR112022009042A2/pt unknown
- 2020-11-11 CA CA3160526A patent/CA3160526A1/en active Pending
-
2022
- 2022-05-01 IL IL292646A patent/IL292646A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7401126B2 (ja) | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 | |
| KR102905497B1 (ko) | 항체-약물 컨쥬게이트와 parp 저해제의 조합 | |
| JP2023509196A5 (OSRAM) | ||
| JP2024037894A5 (OSRAM) | ||
| JP2020528750A5 (OSRAM) | ||
| JP2020502271A5 (OSRAM) | ||
| TW202019487A (zh) | 抗體-藥物結合物及微管蛋白抑制劑之組合 | |
| JP2019532056A5 (OSRAM) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| JP2010535713A5 (OSRAM) | ||
| JP2017514795A5 (OSRAM) | ||
| TW202210507A (zh) | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 | |
| WO2016033324A1 (en) | Internalizing moieties for treatment of cancer | |
| TW202537975A (zh) | 抗體－藥物結合物之製造方法 | |
| RU2006132466A (ru) | Высококонцентрированные жидкие композиции анти-egfr антител | |
| CN106459200A (zh) | 抗‑egfr抗体及抗体药物偶联物 | |
| EP4523704A1 (en) | Camptothecin derivative and ligand-drug conjugate | |
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2025509266A5 (OSRAM) | ||
| JP2024504331A5 (OSRAM) | ||
| JP2025508380A5 (OSRAM) | ||
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 |